How long is the treatment cycle of icorituzumab and what is the treatment effect?

Epcoritumab (Epcoritamab) is a bispecific T-cell ligation antibody (BiTE) jointly developed by Genmab and AbbVie. It specifically targets the dual sites of CD3 and CD20 and is used to activate T cells to directly kill B-cell malignant tumors that express CD20. It has shown significant efficacy in relapsed or refractory large B-cell lymphoma (LBCL; non-Hodgkin lymphoma). The drug is administered by subcutaneous injection, and the treatment cycle is mainly divided into an initial phase and a maintenance phase.

In clinical practice, treatment usually starts with a weekly injection and continues for several weeks to ensure that the body's immune system gradually adapts to the immune-activating effect of the drug and reduces the risk of serious immune-related adverse reactions. Then it enters the maintenance phase of once every two weeks, and then once every four weeks. This gradually decreasing dosing frequency helps to sustain the treatment effect and improve patient compliance. The entire treatment cycle depends on the individual response. It is generally recommended to continue treatment until the disease is relieved or intolerable side effects occur.

In terms of therapeutic effect, icorituzumab has shown encouraging efficacy in multiple international multi-center trials. Especially in patients who have received multiple lines of treatment but have relapsed or failed to respond, its objective response rate (ORR) and complete response rate (CR) are both better than traditional chemotherapy or monoclonal antibody therapy. By activating the patient's own T cells and guiding them to recognize and destroy tumor B cells, the drug achieves the immune system's "re-education" of tumors and lasting immune memory.

Therefore, in some cases, the condition can be maintained stable even after the drug is stopped. Although icarelatumumab is still an emerging therapy, its advantages in sustained immune response, reduced relapse rate, and prolonged survival have gradually emerged, and it is particularly suitable for personalized immunotherapy pathways after the failure of traditional therapies.

Reference materials:https://www.drugs.com/epcoritamab.html